Cihan Gani
@GI_RadOnc
Followers
1K
Following
3K
Media
270
Statuses
1K
👉 Radiation Oncologist 📗 Editor-in-Chief ctRO 🧲 MR guided radiotherapy ⏩ Gastrointestinal Radiation Oncology
Tübingen / Germany
Joined August 2013
Thanks for your great hospitality!
0
0
9
👍
Great to see the updated BCLC guidelines include RT! RT now incorporated into most major guidelines for HCC (BCLC, AASLD, EASL, NCCN, others) & should be a standard of care option. Full link here: https://t.co/EagzIPdmVL
@OncoAlert
0
0
3
Here's a quick tour through our new Center for Adaptive Radiotherapy with @Elekta's 1.5 T MR-Linac and EVO systems bunker to bunker!
0
1
4
Deeply honored to receive the Honorary Fellow (FACR) award from the American College of Radiology — the first ever awarded to a Turkish Radiation Oncologist since 1947. 🇹🇷 Grateful to my mentors, colleagues, and family for their endless support. #FACR #ACR
Prof. Dr. Banu Atalar Will Receive the “Honorary Fellowship” Award from the American College of Radiology🏆 https://t.co/wPfaSQ2fTk
@banu_atalar , @RadiologyACR
1
2
27
New in #practicalRO: Celiac Plexus Radiosurgery for the Management of Pancreatic Cancer Pain: Key Tips and Considerations. https://t.co/782OwzeJi2
0
17
38
Top Clinical Trials at ESTRO 2025: Organ Preservation and Quality of life after Total Neoadjuvant Therapy for LA Rectal Cancer @GI_RadOnc
https://t.co/3XcwSRyyyG
#Cancer #CancerResearch #Medicine #Health #MedX #MedNews #MedEd #RectalCancer #TotalNeoadjuvantTherapy #Oncology
1
2
13
What a great day! Yesterday we went live with Comprehensive Motion Management for our MR-Linac! Thanks to everybody who made this possible! @BoekeSimon @MarcelNachbar @D_Thorwarth @MaxNiyazi @Monica_LoRusso @Elekta @mr_linac @DFG__Official
1
9
36
ASTRO abstracts are no longer embargoed after 5PM EST 9/27. Here is LBA1: PARTIQoL, Phase III study of protons vs IMRT for LR/IR prostate cancer. No significant differences in tumor control or patient-reported quality of life out to 60 months of follow up. #radonc
7
34
108
Join us in Tübingen for the first edition of the Nikolaus-Symposium! Fantastic line-up of international speakers! @alison_tree @stef_corradini @IvanVogelius @LangTanadini @degro_ev @ESTRO_RT @MaxNiyazi @BoekeSimon @D_Thorwarth @uktuebingen @UKT_RadOnc @MedTuebingen
2
9
22
Real-world data on DPYD activity in the context of radiotherapy. Here is our institutional data published by #ElginHoffmann from @UKT_RadOnc #radonc 🔹8% with decreased DPYD activity 🔹No increased toxicity after dose adjustment https://t.co/VkS8iAGwAe
pubmed.ncbi.nlm.nih.gov
With dose reduction in heterozygous patients, toxicity was within the range of patients without DPYD variants. Our clinical data suggest that dose-adapted 5‑FU-/capecitabine-chemoradiotherapy...
0
2
12
Applicability of adaptive trials design and platform studies - tips from the amazing Saskia Litiere #ESMO24
@EORTC @AACR @myESMO
@OncoAlert #OncoAlert #clinicaltrial
0
7
22
ADRIATIC is a practice changing trial for LS-SCLC with consolidation durvalumab after chemo radiation demonstrating superior progression free and overall survival over chemo radiation alone. A long awaited change in standard of care! Another win for lung cancer patients.
Presented at #ESMO24: Among patients with limited-stage small-cell lung cancer, overall and progression-free survival were significantly longer with durvalumab adjuvant therapy added to standard concurrent chemoradiotherapy. Full ADRIATIC trial results: https://t.co/G6gpxMMCkV
0
7
29
Fantastic data - we implemented this treatment immediately after the results were presented at ASCO GI and are impressed by the outcomes. Congrats to @ldawsonmd !!!!
Online First: #Palliative #radiotherapy versus best supportive care in patients with painful #hepaticcancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study #radonc
https://t.co/BYHtpmo9SO
0
2
25
Online First: #Palliative #radiotherapy versus best supportive care in patients with painful #hepaticcancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study #radonc
https://t.co/BYHtpmo9SO
0
20
46